

Table S1 Clinical characteristics and surgical outcomes stratified by PD-L1 expression status (TPS)

Characteristics	TPS $\geq 1\%$ (n=37)	TPS 0% (n=21)	P value	PD-L1 $\geq 50\%$ (n=11)	PD-L1 $< 50\%$ (n=47)	P value
Age (years)	68 [47–82]	69 [56–79]	0.13	69 [58–79]	69 [47–82]	0.86
Sex			1			1
Male	33 (89.2)	19 (90.5)		10 (90.9)	42 (89.4)	
Female	4 (10.8)	2 (9.5)		1 (9.1)	5 (10.6)	
Tumor location			0.9			0.71
Right	27 (73.0)	15 (71.4)		7 (63.6)	35 (74.5)	
Left	10 (27.0)	6 (28.6)		4 (36.4)	12 (25.5)	
Histological subtype			0.27			0.055
Epithelioid	25 (67.6)	17 (81.0)		5 (45.5)	37 (78.7)	
Sarcomatoid	8 (21.6)	2 (9.5)		5 (45.5)	5 (10.6)	
Biphasic	4 (10.8)	2 (9.5)		1 (9.1)	5 (10.6)	
Pathological stage			0.63			0.02
IA/IB	4 (10.8)/18 (48.6)	4 (19.0)/11 (52.4)		2 (18.2)/3 (27.3)	6 (12.8)/26 (55.3)	
II	1 (2.7)	1 (4.8)		0 (0)	2 (4.2)	
IIIA/IIIB	5 (13.5)/9 (24.3)	3 (14.3)/2 (9.5)		3 (0)/6 (54.5)	8 (17.0)/5 (10.6)	
IV	0	0		0	0	
Resectability status			1			1
R1	34 (91.9)	19 (90.5)		10 (90.9)	43 (91.5)	
R2	3 (8.1)	2 (9.5)		1 (9.1)	4 (8.5)	
Extended P/D	33 (89.2)	18 (85.7)	1	8 (72.7)	43 (91.5)	0.12
Operative time (min)	381 [204–884]	380 [225–556]	0.35	401 [255–491]	380 [204–884]	0.77
Intraoperative blood loss (mL)	1,650 [750–9,100]	1,850 [420–4,210]	0.75	2,070 [1,080–2,960]	1,650 [420–9,100]	0.16
Adjuvant chemotherapy	27 (73.0)	16 (76.1)	0.92	6 (54.5)	37 (78.7)	0.12

Data are presented as median [range] or n (%). P/D, pleurectomy/decortication; PD-L1, programmed death 1 ligand-1; TPS, tumor proportion score.

Table S2 Univariable Cox regression analyses of overall survival and relapse-free survival in patients with epithelioid pleural mesothelioma

Variables	Univariable					
	Overall survival			Relapse-free survival		
	Hazard ratio	95% CI	P value	Hazard ratio	95% CI	P value
Age, <70 years (vs. ≥70 years)	0.36	0.15–0.91	0.03	0.97	0.45–2.08	0.93
Sex, female (vs. male)	1.22	0.35–4.22	0.75	1.06	0.36–3.07	0.92
Tumor location, left (vs. right)	0.73	0.28–1.93	0.53	1.20	0.51–2.85	0.67
Procedure, P/D (vs. extended P/D)	1.11	0.32–3.83	0.87	0.96	0.33–2.79	0.95
Pathological stage, IA (vs. IB–IV)	0.03	0–2.93	0.13	0.32	0.09–1.08	0.07
PD-L1, TPS 0% (vs. ≥1%)	0.57	0.21–1.52	0.26	0.31	0.13–0.72	0.07
PD-L1, TPS <50% (vs. ≥50%)	0.51	0.15–1.78	0.29	0.61	0.21–1.78	0.36
Adjuvant chemotherapy, yes (vs. no)	0.26	0.10–0.69	0.007	0.69	0.24–2.02	0.50

CI, confidence interval; P/D, pleurectomy decortication; PD-L1, programmed death 1 ligand-1; TPS, tumor proportion score.

Table S3 Multivariable Cox regression analyses of overall survival and relapse-free survival in patients with epithelioid pleural mesothelioma

Variables*	Multivariable					
	Overall survival			Relapse-free survival		
	Hazard ratio	95% CI	P value	Hazard ratio	95% CI	P value
Model 1 [†]						
Age, <70 years (vs. ≥70 years)	0.34	0.13–0.87	0.02	–	–	–
Sex, female (vs. male)	–	–	–	–	–	–
Tumor location, left (vs. right)	–	–	–	–	–	–
Procedure, P/D (vs. extended P/D)	–	–	–	–	–	–
Pathological stage, IA (vs. IB–IV)	–	–	–	0.39	0.11–1.32	0.13
PD-L1, TPS 0% (vs. ≥1%)	–	–	–	0.35	0.15–0.81	0.01
Adjuvant chemotherapy, yes (vs. no)	0.24	0.09–0.66	0.006	–	–	–
Model 2 [‡]						
Age, <70 years (vs. ≥70 years)	0.34	0.13–0.87	0.02	–	–	–
Sex, female (vs. male)	–	–	–	–	–	–
Tumor location, left (vs. right)	–	–	–	–	–	–
Procedure, P/D (vs. extended P/D)	–	–	–	–	–	–
Pathological stage, IA (vs. IB–IV)	–	–	–	–	–	–
PD-L1, TPS <50% (vs. ≥50%)	–	–	–	–	–	–
Adjuvant chemotherapy, yes (vs. no)	0.24	0.09–0.66	0.006	–	–	–

*, multivariable models included variables with P<0.10 in the univariable analysis; [†], model 1 includes PD-L1 status as TPS ≥1% vs. 0%;

[‡], model 2 includes PD-L1 status as TPS ≥50% vs. <50%. CI, confidence interval; P/D, pleurectomy decortication; TPS, tumor proportion score.




Figure S1 Overall survival (A) and relapse-free survival (B) after P/D stratified by histological subtype (C,D). MST, median survival time; P/D, pleurectomy/decortication.




Figure S2 Overall survival and relapse-free survival after P/D stratified by PD-L1 expression. Comparisons between TPS 0% *vs.* $\geq 1\%$ (A,B) and TPS <50% *vs.* TPS $\geq 50\%$ (C,D). P/D, pleurectomy/decortication; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.




Figure S3 Overall survival and relapse-free survival after P/D in patients with epithelioid subtype stratified by PD-L1 expression. Comparisons between TPS 0% *vs.* $\geq 1\%$ (A, B) and TPS <50% *vs.* TPS $\geq 50\%$ (C,D). P/D, pleurectomy/decortication; TPS, tumor proportion score.




Figure S4 Overall survival and relapse-free survival after P/D in patients with non-epithelioid subtype stratified by PD-L1 expression. Comparisons between TPS 0% *vs.* $\geq 1\%$ (A,B) and TPS <50% *vs.* TPS $\geq 50\%$ (C,D). P/D, pleurectomy/decortication; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.